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Abstract
Cystic periventricular leukomalacia is commonly diagnosed in premature infants, resulting from severe hypoxic-
ischemic white matter injury, and also involving some grey matter damage. Very few is known concerning the cell
death pathways involved in these types of premature cerebral lesions. Excitotoxicity is a predominant mechanism of
hypoxic-ischemic injury in the developing brain. Concomitantly, it has been recently shown that autophagy could be
enhanced in excitotoxic conditions switching this physiological intracellular degradation system to a deleterious
process. We here investigated the role of autophagy in a validated rodent model of preterm excitotoxic brain damage
mimicking in some aspects cystic periventricular leukomalacia. An excitotoxic lesion affecting periventricular white and
grey matter was induced by injecting ibotenate, a glutamate analogue, in the subcortical white matter (subcingulum
area) of ﬁve-day old rat pups. Ibotenate enhanced autophagy in rat brain dying neurons at 24 h as shown by increased
presence of autophagosomes (increased LC3-II and LC3-positive dots) and enhanced autophagic degradation
(SQSTM1 reduction and increased number and size of lysosomes (LAMP1- and CATHEPSIN B-positive vesicles)).
Co-injection of the pharmacological autophagy inhibitor 3-methyladenine prevented not only autophagy induction
but also CASPASE-3 activation and calpain-dependent cleavage of SPECTRIN 24 h after the insult, thus providing a
strong reduction of the long term brain injury (16 days after ibotenate injection) including lateral ventricle dilatation,
decreases in cerebral tissue volume and in subcortical white matter thickness. The autophagy-dependent
neuroprotective effect of 3-methyladenine was conﬁrmed in primary cortical neuronal cultures using not only
pharmacological but also genetic autophagy inhibition of the ibotenate-induced autophagy. Strategies inhibiting
autophagy could then represent a promising neuroprotective approach in the context of severe preterm brain injuries.
Introduction
The important progress done in neonatal care con-
stantly increases the survival rates of premature infants.
Conversely, the proportion of neurological disabilities
developed by survivors is hardly reduced especially for
those with severe impairment. One of them is the diplegic
cerebral palsy, called also spastic diplegia of Little1,
affecting still between 3–7% of very low birth weight
(VLBW) infants2,3. The strongest predictor of this
form of cerebral palsy in VLBW infants is cystic peri-
ventricular leukomalacia (cPVL)4, a form of preterm
white matter (WM) injury adjacent to the lateral ven-
tricles, which occurs either from a hypoxic-ischemic
(HI) event around birth or after infectious events such
as septic shock, necrotizing enterocolitis or even reported
after viral infections5,6. Improving the outcomes for
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these severely affected babies remains a challenging
health issue.
Beside inﬂammation and reactive oxygen species for-
mation, excitotoxicity seems to be crucial in the patho-
physiology of many preterm brain injuries such as
PVL3,7,8. Excitotoxicity consists in an excessive or pro-
longed activation of excitatory amino acid receptors
(especially those of glutamate) due to a failure of sufﬁcient
reuptake and/or excessive release at the synaptic level. It
induces a massive increase in intracellular calcium con-
centration and thus activates numerous intracellular
cascades potentially leading to neuronal cell death9,10.
Glutamate homeostasis is highly important for human
brain development (proliferation, migration, differentia-
tion, survival processes and synapses reﬁnement)11.
However it also confers to immature brain a vulnerability
to excitotoxic injuries since a higher level of ionotropic
glutamate receptors are expressed in developing brain
compared to that of adult8,12–15. These receptors are in
addition more readily activated. Excitotoxic lesions can
occur following a panel of deleterious events (that can be
related) such as infection/inﬂammation, hypoxia and/or
ischemia. Excitotoxicity is then a common pathological
mechanism of various perinatal brain injuries. In neurons
the peak of expression of NMDA receptors appears to
occur at term in which grey matter (GM) damage is
predominant than in preterm13. In human WM, this
peak occurs in preterm brain glial cells, especially in
pre-oligodendrocytes O4+, and contributes to the high
sensitivity of preterm WM. PVL was mainly thought
to be associated to WM injury but it is clearly shown now
that GM damage is also often involved in a “neuronal-
axonal disease”16,17.
Experimental research has revealed the complexity of
the pathophysiology of excitotoxic death showing multi-
ple and interrelating cell death mechanisms reﬂected by
mixed features of neuronal death including not only the
well-known “apoptotic-necrotic continuum” with features
of apoptosis and necrosis in the same dying neurons18 but
also characteristics of enhanced macroautophagy10,19–21.
Autophagy is a physiological cellular mechanism of
degradation and recycling of dysfunctioning long lived
proteins and organelles22. Its main form (macro-
autophagy, hereafter called autophagy), consists in the
formation of a multimembrane intermediate compart-
ment, named autophagosome, that engulfs part of the
cytosol containing proteins and organelles to be degraded.
The autophagosome then fuses with a lysosome, forming
an autolysosome, to degrade its content through lysoso-
mal hydrolases activity22. Autophagy is thus essential for
cellular homeostasis and could be used as a survival
response to different stresses such as nutrients depriva-
tion, accumulation of toxic proteins or pathogen inva-
sion23. However, dysregulated increase in autophagic
process has been also implicated in cell death as an
independent mechanism (termed “autophagic cell death”)
or more frequently as a mediator of other types of cell
death, mainly apoptosis, and then designed as “autophagy-
mediated cell death”10,24–28. Abnormal high level of
autophagosomes and autolysosomes with increased lyso-
somal enzyme activity were often observed in dying
neurons in models of excitotoxicity including perinatal
cerebral HI19,20,29–31. Interestingly, we also recently
demonstrated excessive autophagic features in post-
mortem brains of human term newborns presenting
severe hypoxic-ischemic encephalopathy (HIE)29,31.
Although controversies remain concerning the role of
autophagic activation24,32–35, most of the studies using
autophagy inhibition, either through pharmacological
inhibitors such as 3-methyladenine (3-MA)30,36–40 or
through speciﬁc and genetic inhibition of autophagy-
related genes (atg)20,29,31,41, have revealed a pro-death role
of autophagy in perinatal and adult cerebral HI models.
The present study aims to determine the role of
autophagy in excitotoxic lesions of the premature brain
using a widely recognized rodent model that mimics some
features of cPVL42. Autophagy ﬂux and the neuropro-
tective effect of autophagy inhibition either pharmacolo-
gically with 3-MA or genetically in neuronal cultures was
investigated in the context of an excitotoxic insult
induced by an injection of the glutamate analogue ibote-
nate. An involvement of autophagy in excitotoxic preterm
brain damage would reveal a new cellular death pathway
and open the way for new neuroprotective strategies in
severe preterm brain injuries.
Results
Ibotenate injection in subcortical WM of rat pups induces
brain injury
As a model mimicking some aspects of cPVL, we
selected a widely recognized model of preterm excitotoxic
brain injury consisting in applying an intracerebral
injection of ibotenate in rat pups42. The injection of ibo-
tenate (10 µg) in the subcortical WM at the level of the
right cingulum of 5-days-old rat pups causes a severe
brain damage of the WM and GM resulting in ventricular
enlargement as illustrated by cresyl-violet-stained coronal
sections in Fig. 1a 24 h and 16 days after the insult.
Immunoblot analysis of two death markers, the calpain-
dependent 150–145 kDa spectrin/fodrin (SPTAN) frag-
ment and cleaved CASPASE-3 (CASP3), indicated an
activation of both calcium-dependent necrotic cell death
and caspase-dependent apoptosis (Fig. 1b) at 6 and 24 h
after the insult (~5 and 14 fold increases respectively at
24 h). Although the proﬁle of CASP3 activation was
similar between females and males, we observed 24 h after
the insult a greater activation (~2 times more) in females.
Double immunolabeling showed that CASP3 was
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activated in neurons (RBFOX3-positive cells) 24 h after
ibotenate injection (Fig. 1c).
Ibotenate injection in subcortical WM of rat pups enhances
autophagic ﬂux in cortical neurons
To study the effect of intracerebral injection of ibote-
nate on autophagy, the expression levels of LC3-II
(the autophagosomal membrane bound form of LC3)
and Sequestosome-1 (SQSTM1, selectively degraded
by autophagy) in ipsilateral cortical extracts was ﬁrst
analyzed at 6 and 24 h after the ibotenate injection
(Fig. 2a). LC3-II was signiﬁcantly enhanced by ibotenate
compared to vehicle treated-rats (increase of 72% at 24 h)
whereas SQSTM1 was decreased (reduction of 23% at
24 h) suggesting an increase in the autophagy ﬂux in
females as well as in males. A quantiﬁcation of the
number of LC3-positive dots per neuron (RBFOX3-posi-
tive cells) conﬁrmed a signiﬁcant increase of 7.9 fold
in the number of autophagosomes in cortical neurons
24 h after the insult (Fig. 2b). Moreover, strong morpho-
logical features of enhanced autophagy could be observed
at the ultrastructural level (Fig. 2c). At earlier stage
(6 h after ibotenate injection), electron microscopy
revealed numerous multimembrane structures containing
undigested cellular contents (autophagosomes) and elec-
tron dense vacuoles containing cytoplasmic materials
Fig. 1 Ibotenate injection in subcortical white matter of rat pups induces brain injury. a Representative cresyl violet-stained coronal sections
illustrating the brain damage 24 h (at 6 postnatal days (P6)) and 16 days (P21) after ibotenate (Ibo) injection. Scale bar: 1 mm. b Ibo injection activates
both 150–145 kDa calpain-dependent cleavage of spectrin/fodrin (SPTAN) (veh: 100 ± 6.3%, 6 h Ibo: 284.4 ± 56.6%, 24 h Ibo: 528.1 ± 88.8%) and those
of caspase-3 (CASP3) (veh: 100 ± 7.13%, 6 h Ibo: 702.6 ± 210%, 24 h Ibo: 1430.9 ± 271.1%) as shown by representative immunoblots and the
corresponding quantiﬁcations. Mean CASP3 value is 870.7 ± 204.1% for males and 1929 ± 423.5% for females at 24 h. Mean SPTAN value is 312.1 ±
55.9% for males and 720.1 ± 132.5% for females at 24 h. (veh: n= 11 females, 10 males; 6 h: n= 7 females, 7 males; 24 h: n= 9 females, 8 males). Males
are represented by black triangles and females by white circles. c CASP3 is activated in neurons as revealed by double immunolabeling against
cleaved CASP3 (in red) and the neuronal marker RNA Binding Protein, Fox-1 Homolog 3 (RBFOX3)/NeuN (in green) 24 h after Ibo injection in neurons.
Scale bar: 20 µm. Values are mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001
Descloux et al. Cell Death and Disease  (2018) 9:853 Page 3 of 16
Ofﬁcial journal of the Cell Death Differentiation Association
at different stages of degradation (autolysomes) whereas
later on (at 24 h) hybrid phenotypes of cell death are
observed in dying neurons including apoptosis-like mor-
phological features (chromatin condensation), enhanced
autophagy (numerous autophagosomes and autolyso-
somes) and swollen organelles.
Finally, in addition to a higher number of autophago-
somes, autolysosomes were also more numerous in
neurons of ibotenate-treated rat pups than in vehicle-
treated animals. Immunohistochemistry and quantiﬁca-
tion of the number and the size of vesicles labeled with
antibodies against either a lysosomal membrane bound
protein, lysosomal-associated membrane protein 1
(LAMP1) (Fig. 3a), or a lysosomal enzyme (CATHEPSIN
B) (Fig. 3b) demonstrated an increase not only in
thenumber but also in the size of either LAMP1
(~4 fold) or CATHEPSIN B (~3 fold) positive-dots,
and especially those larger than 0.5 µm2 (increase of
29 and 23%, respectively) that are presumably autolyso-
somes. These results showed that ibotenate resulted in
enhancement of neuronal autophagy in the damaged
cortex of rat pups.
Fig. 2 Ibotenate injection in subcortical white matter of rat pups enhances autophagy in neurons. a Representative immunoblots and the
corresponding quantiﬁcations demonstrate an increase in LC3-II (veh: 100 ± 3.3%, 6 h Ibo: 125.6 ± 8.9%, 24 h Ibo: 173.2 ± 16.4%) and a decrease in
SQSTM1 (veh: 100 ± 1.7%, 6 h Ibo: 80.5 ± 2.4%, 24 h Ibo: 77.3 ± 4%) level of expression from 6 h after ibotenate (Ibo) injection. Mean LC3-II value
is 146.9 ± 12% for males and 196.6 ± 27.5% for females at 24 h. Mean SQSTM1 value is 81 ± 4.4% for males and 74 ± 6.5% for females at 24 h.
(veh: n= 11 females, 10 males; 6 h: n= 7 females, 7 males; 24 h: n= 9 females, 8 males). b Quantiﬁcation of LC3-positive dots (in red) per neuron
((RNA Binding Protein, Fox-1 Homolog 3) RBFOX3/NeuN (in green)) per µm2 on confocal images shows an increase in the number of
autophagosomes in the cortex 24 h after Ibo injection (veh: 0.0131 ± 0.001, Ibo: 0.1039 ± 0.0083). Mean LC3-positive dots per neuron per µm2 value is
0.1366 ± 0.0137% for males and 0.0711 ± 0.0079% for females treated with Ibo. Males are represented by black triangles and females by white circles.
Values are mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001. Scale bars: 20 µm. c Ultrastructure analysis of damaged cortex reveals the presence of
numerous autophagosomes (multimembrane vacuoles, arrow heads) and autolysosomes (electron dense structures, arrows) in the cytosol at 6 and
24 h. Nuclear chromatin condensation and swollen organelles are observed at later stage (24 h). Nucleus (N). Scale bars: 1 µm
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Ibotenate induced-autophagy and -cell death are reduced
by pharmacological inhibition of autophagy
We then evaluated the role of this enhanced neuronal
autophagy on brain damage. Since long term autophagy
inhibition could be potentially deleterious particularly
for neurons43, we decided to manage the transient
inhibition of autophagy with the widely used pharmaco-
logical inhibitor of autophagy 3-MA. 3-MA was admi-
nistered in the ipsilateral ventricle just before ibotenate
injection as previously done in ischemic rat pups30.
As shown by immunoblots, ibotenate-induced increase
in LC3-II expression levels at 24 h was reduced by
Fig. 3 Ibotenate injection in subcortical white matter of rat pups increases autolysosomes formation in neurons. a Quantiﬁcation of LAMP1-
positive dots (in red) per neuron (MAP2 (in green)) per µm2 on confocal images shows an increase in the number of LAMP1-positive lysosomes in the
cortex 24 h after Ibo injection (number of dots: veh: 0.018 ± 0.002, Ibo: 0.075 ± 0.003/neurons/µm2). Mean value is 0.089 ± 0.005% for males and 0.057
± 0.004% for females treated with Ibo. On average, the measure of their size reveals the presence of larger LAMP1-positive dots following Ibo
injection (mean dot area: veh: 0.171 ± 0.002, Ibo: 0.685 ± 0.049 µm2) resulting from more dots larger than 0.5 µm2 (veh: 7.08 ± 1.90%, Ibo: 35.56 ±
2.08%). Mean value is 0.571 ± 0.051 µm2 / 38.3 ± 3.4% for males and 0.849 ± 0.091 µm2/38.3 ± 3.4% for females treated with Ibo. b Quantiﬁcation
of CATHEPSIN B (CTSB)-positive dots (in red) per neuron ((RNA Binding Protein, Fox-1 Homolog 3) RBFOX3/NeuN (in green)) conﬁrms an increase
not only in the number (number of dots: vehM+F: 0.047 ± 0.003, IboM+F: 0.153 ± 0.004, IboM: 0.153 ± 0.005, IboF: 0.153 ± 0.007/neurons/µm
2) but
also in the size of lysosome (mean dot area: vehM+F: 0.146 ± 0.009, IboM+F: 0.460 ± 0.020 µm
2, IboM: 0.490 ± 0.025 µm
2, IboF: 0.343 ± 0.021 µm
2;
dots > 0.5 µm2: vehM+F: 3.033 ± 0.723%, IboM+F: 26.10 ± 1.274%, IboM: 26.8 ± 1.3%, IboF: 18.6 ± 2.1%). Scale bars: 20 µm. Values are mean ± SEM,
*p < 0.05; **p < 0.01; ***p < 0.001. (veh: n= 63 females, 30 males; Ibo: n= 35 females, 140 males). Males are represented by black triangles and
females by white circles
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36% in 3-MA-treated rats compared to saline-injected
rats (Fig. 4a). Moreover, SQSTM1 expression levels
were also signiﬁcantly increased by 26% with 3-MA
treatment conﬁrming an efﬁcient inhibition of autophagy
by 3-MA (Fig. 4a). We then evaluated the effect of
autophagy inhibition on cell death markers at 24 h.
The expression levels of both the 150–145 kDa SPTAN
fragment and cleaved CASP3 were signiﬁcantly decreased
by 64 and 62% respectively with 3-MA treatment (Fig. 4b)
demonstrating that autophagy inhibition by 3-MA
could be neuroprotective 24 h after the induction of the
excitotoxic brain lesion. Moreover 3-MA treatment was
as efﬁcient in females as well as in males.
Long term ibotenate-induced brain damage is strongly
reduced by pharmacological inhibition of autophagy
We then evaluated the long term beneﬁt of 3-MA-
mediated autophagy inhibition on brain injury at P21
(16 days after ibotenate injection). As shown in Figs. 5a, 3-
MA treated-brains were less sensitive to ibotenate-
induced damage. The ventricle enlargement of ~20 fold
produced by ibotenate injection was strongly prevented by
Fig. 4 Ibotenate induced-autophagy and cell death is reduced by pharmacological inhibition of autophagy. a Intracerebroventricular
injection of the autophagy inhibitor 3-methyladenine (3-MA) just before ibotenate (Ibo) treatment decreases LC3-II (Ibo+ 3-MA: 64.1 ± 5.3%) and
increases SQSTM1 (Ibo+ 3-MA: 126.5 ± 4.6%) levels 24 h after Ibo injection compared to rat pups treated with saline (Ibo+ saline: LC3, 100 ± 3.5%;
SQSTM1, 100 ± 3.5%) as shown by representative immunoblots of cortical extracts and the corresponding quantiﬁcations. Mean LC3-II value is 55.6 ±
6.7% for males and 71.5 ± 7.7% for females at 24 h. Mean SQSTM1 value is 127.4 ± 7.2% for males and 127.5 ± 7.07% for females at 24 h. b 3-MA
prevents both 150–145 kDa calpain-dependent cleavage of spectrin/fodrin (SPTAN) (Ibo+ saline: 100 ± 8.8%, Ibo+ 3-MA: 51.5 ± 12.9%) and those of
caspase-3 (CASP3) (Ibo+ saline: 100 ± 9.1%, Ibo+ 3-MA: 55.8 ± 14.4%). Mean SPTAN value is 21.7 ± 4.3% for males and 52.7 ± 12.9% for females at
24 h. Mean CASP3 value is 25.8 ± 6.1% for males and 44.8 ± 13.7% for females at 24 h. Values are mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001. (Ibo
+ saline: n= 15 females, 10 males; Ibo+ 3-MA: n= 16 females, 14 males). Males are represented by black triangles and females by white circles
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Fig. 5 Long term ibotenate-induced brain damage is strongly reduced by pharmacological inhibition of autophagy. a Representative cresyl
violet-stained coronal sections of brain 16 days (P21) after injury illustrating the protective effect of the autophagy inhibitor 3-methyladenine (3-MA)
injected in the ipsilateral ventricle just before ibotenate (Ibo). Scale bar: 1 mm. b 3-MA treatment reduces Ibo-induced ventricle dilatation (veh+
saline: 0.386 ± 0.086%, Ibo+ saline: 7.655 ± 1.233%, Ibo+ 3-MA: 0.646 ± 0.112%, veh+ 3MA: 0.366 ± 0.056%). Mean values for Ibo+ saline treatment
are 6.88 ± 1.38% for males and 8.10 ± 1.79% for females whereas those for Ibo+ 3-MA are 0.53 ± 0.16% for males and 0.78 ± 0.21% for females.
c Quantiﬁcation of ipsilateral surviving tissue volume (veh+ saline: 49.94 ± 0.167%, Ibo+ saline: 41.41 ± 1.486%, Ibo+ 3-MA: 49.22 ± 0.379%, veh+
3MA: 49.43 ± 0.428%) relatively to total brain volume and more speciﬁcally those of the ipsilateral cortex (veh+ saline: 24.09 ± 0.258%, Ibo+ saline:
18.76 ± 0.926%, Ibo+ 3-MA: 23.13 ± 0.329%, veh+ 3MA: 23.78 ± 0.170%) shows that Ibo-induced decrease in brain tissue volume is prevented by
3-MA. Mean surviving tissue volumes for Ibo+ saline treatment are 42.11 ± 1.68% for males and 41.02 ± 2.16% for females whereas those for Ibo+
3-MA are 49.92 ± 0.34% for males and 48.45 ± 0.59% for females. d. 3-MA attenuates the Ibo-induced decrease in the thickness of white matter
located at three different levels: corpus callosum (veh+ saline: 452.61 ± 17.16 µm, Ibo+ saline: 394.72 ± 28.76 µm, Ibo+ 3-MA: 490.73 ± 11.08 µm,
veh+ 3MA: 433.67 ± 19.19 µm), cingulum region (veh+ saline: 617.54 ± 21.96 µm, Ibo+ saline: 369.76 ± 37.63 µm, Ibo+ 3-MA: 560.37 ± 35.46 µm,
veh+ 3MA: 592.40 ± 37.53 µm) and at the beginning of the external capsule (veh+ saline: 337.89 ± 18.44 µm, Ibo+ saline: 269.80 ± 16.23 µm, Ibo+
3-MA: 358.28 ± 19.20 µm, veh+ 3MA: 338.05 ± 24.81 µm). 3-MA tends to have a similar protective effect on white matter thickness in males and
females. Values are mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001. (veh+ saline: n= 6 females, 5 males, Ibo+ saline: n= 16 females, 9 males, Ibo+
3-MA: n= 8 females, 9 males, veh+ 3MA: n= 3 females, 3 males). Males are represented by black triangles and females by white circles
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3-MA treatment (reduced to only 1.7 fold) (Fig. 5b).
Moreover, ibotenate-induced tissue loss of 8.54% (total
ipsilateral WM and GM), with a decrease of 5.33%
speciﬁcally for cortex (total ipsilateral intact cortex), was
also, on average, signiﬁcantly prevented in 3-MA-treated
rats compared to saline-treated rats (Fig. 5c).
To evaluate the effect of ibotenate on WM, the thick-
ness of the subcortical WM was measured at three dif-
ferent levels around the ibotenate injection site. Reduced
thickness could reﬂect an indirect effect of the GM lesion
with secondary axonal degeneration and/or a direct
excitotoxic effect on immature oligodendrocytes. A sig-
niﬁcant decrease in the thickness of subcortical WM of
13% for corpus callosum, 40% for the WM located at the
level of cingulum and 20% for external capsule was
detected in ibotenate-treated brains (Fig. 5d). These WM
alterations were not observed when 3-MA was co-injected
with ibotenate (Fig. 5d).
Taken together, these data showed a long term bene-
ﬁcial effect of pharmacological autophagy inhibition
against ibotenate-induced brain damage that was more-
over observed both in males and females.
An excitotoxic dose of ibotenate enhances autophagic ﬂux
in primary cortical neuronal cultures
In order to conﬁrm that ibotenate could enhance
autophagy and that speciﬁc autophagy inhibition could be
neuroprotective against ibotenate-mediated excitotoxi-
city, we then decided to evaluate the effect of an excito-
toxic dose of ibotenate on autophagy in primary cortical
neuronal cultures. In general, 50 µM of ibotenate pro-
moted neuronal death as suggested by a 3 and 14 fold
increase in lactate deshydrogenase (LDH) release in the
culture medium 3 and 6 h, respectively after ibotenate
treatment (Fig. 6a). This LDH release was abolished by
MK801 or EGTA pretreatment (data not shown) con-
ﬁrming excitotoxic mechanisms (NMDA receptors over-
activation and calcium overload).
As shown in Fig. 6b, activation of autophagy occurred
along with neuronal death since both LC3-II expression
and SQSTM1 degradation were increased at 3 and 6 h. In
order to conﬁrm an enhanced autophagic ﬂux, ibotenate
was ﬁrst applied in the presence of lysosomal enzymes
inhibitors (Fig. 6c). A combination of E64 and pepstatin
A1 (PepA) (10 μg/ml) induced an accumulation of both
LC3-II (of 123%) and SQSTM1 (of 13%) reﬂecting the
failure in the autophagy degradation step. When ibotenate
was applied 4 h after E64/PepA, LC3-II and SQSTM1
accumulations were even greater (174 and 21% respec-
tively), demonstrating that ibotenate treatment triggered
the new formation of autophagosomes and thus con-
ﬁrming that ibotenate treatment increased the autopha-
gosome biogenesis. Second, autophagic ﬂux was
monitored using the tandem mRFP-GFP-LC3 plasmid
that allows to discriminate between LC3 expressed in
neutral compartments (GFP+ RFP+; early autophago-
somes: i.e. autophagosomes before fusion with lysosomes)
and in acidic vesicles (GFP-RFP+; i.e., late autophago-
somes: autophagosomes after fusion with lysosomes
(autolysosomes)) thanks to the pH sensitivity differences
exhibited by the two ﬂuorescent proteins (Fig. 6e). A
quantiﬁcation of the different LC3-positive dots per
neuron per µm2 clearly demonstrated that both autop-
hagosomes formation (~5 fold increase of GFP+ RFP+
dots) and their fusion with the lysosomes (~13 fold
increase of GFP−RFP+ dots) were enhanced by ibotenate
treatment. Taken together, these results on cortical neu-
ronal cultures allow to conclude that an excitotoxic dose
of ibotenate was efﬁcient to induce a boost of neuronal
autophagic ﬂux.
Pharmacological and genetic inhibition of autophagy is
protective against ibotenate-induced excitotoxicity in
primary cortical neuronal cultures
We then assessed the functional role of the ibotenate-
enhanced autophagy in primary cortical neuronal cul-
tures. We ﬁrst used 3-MA. Pre-treatment with 3-MA (10
mM) prevented the increases in both LC3-II expression
and SQSTM1 degradation at 6 h after ibotenate treatment
(Fig. 7a). 3-MA displayed a signiﬁcant neuroprotective
effect as shown by a decrease of 26% in LDH release
(Fig. 7b). Interestingly, blocking lysosomal degradation
with E64/PepA also reduced neuronal death (Fig. 7c)
suggesting a role of autophagy degradation step in
ibotenate-induced neurotoxicity.
Then, in order to inhibit more speciﬁcally autophagy,
downregulation of the expression of two important
autophagy proteins (ATG7 and BECLIN1 (BECN1)) was
performed using lentiviral vectors transducing short
hairpin RNAs (shRNAs) (Fig. 8a). Transduction of cul-
tured primary cortical neurons with Atg7 and Becn1
shRNAs resulted in an efﬁcient inhibition of autophagy as
demonstrated by a decrease in both LC3-II expression and
SQSTM1 degradation (Figs. 8b, c). The death-promoting
role of enhanced autophagy in ibotenate-induced neuro-
nal death was conﬁrmed by a reduction of ~30% of LDH
release when ATG7 and BECN1 were downregulated
(Fig. 8d).
In conclusion, these in vitro data conﬁrmed that an
excitotoxic dose of ibotenate could induce autophagy-
mediated neuronal death and that targeting autophagy
inhibition could lead to neuroprotection.
Discussion
In the present study, we investigated for the ﬁrst time
the role of autophagy in a preclinical model of premature
brain damage related to cPVL42. The effect of ibotenate
injection on rodent brain development is highly
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Fig. 6 Excitotoxic dose of ibotenate enhances autophagic ﬂux in primary cortical neuronal cultures. a Ibotenate (Ibo, 50 µM) is neurotoxic as
shown by lactate deshydrogenase (LDH) release in the culture medium of cultured neurons (veh: 7.4 ± 1.1%, 1h30: 6.4 ± 0.9%, 3 h: 21 ± 1.9%, 6 h: 100
± 3.2%). b Representative immunoblots and the corresponding quantiﬁcations demonstrate an increase in LC3-II (veh: 100 ± 2.7%, 1h30: 110.4 ± 4.6%,
3 h: 132.3 ± 8.5%, 6 h: 147.6 ± 6.6%) and a decrease in SQSTM1 (veh: 100 ± 1.5%, 1h30: 89.7 ± 3.3%, 3 h: 88.1 ± 4.4%, 6 h: 84.2 ± 4.4%) level of expression
following Ibo treatment. c Addition of pepstatin A (PepA) and E64 prevents lysosomal degradation as shown by increases in the level of LC3-II (veh
Pep/E64: 223.2 ± 14.3%) and SQSTM1 (veh Pep/E64: 113 ± 2.8%) relative to neurons treated with DMSO (veh DMSO; LC3-II: 100 ± 3.3%, SQSTM1: 100 ±
2.6%). When added 4 h before Ibo (3 h), PepA/E64 treatment results in a greater increase in LC3-II (Ibo E64/PepA: 274.1 ± 19.9%) than treatment with
E64/PepA or Ibo alone (Ibo DMSO: 148.7 ± 6.7%). E64/PepA pretreatment inhibits the Ibo-induced degradation of SQSTM1 (Ibo DMSO: 84.4 ± 2.2%;
Ibo E64/PepA: 120.8 ± 5.5%). d Representative confocal images of cultured neurons transfected with the tandem mRFP-GFP-LC3–expressing plasmid
6 h after Ibo addition. Quantiﬁcation of the number of LC3-positive dots per neuron per µm2 demonstrates an enhanced functional autophagic ﬂux
(Total= GFP+ RFP+ and GFP−RFP+ : veh: 0.024 ± 0.003, Ibo: 0.174 ± 0.016; GFP+ RFP+ (early autophagosomes): veh: 0.015 ± 0.002, Ibo: 0.076 ±
0.007; GFP−RFP+ (autolysosomes) veh: 0.008 ± 0.001, Ibo: 0.100 ± 0.011). Scale bar: 10 µm.Values are mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001
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dependent of the age. If injected around P5, when neu-
ronal migration is completed, the model mimics some of
the preterm brain injury features42. Human preterm WM
injury is often observed with GM developmental altera-
tion and/or damage (neuronal-axonal disease)2,3,16,17,44.
Persistent cerebral volume reduction and ven-
triculomegaly are also observed in premature infants
compared to full-term45,46. The injection of ibotenate
in the subcortical WM at the level of the right cingulum
caused a severe lesion in rat pups and led to reduced
subcortical WM thickness, signiﬁcant loss of tissue and
important lateral ventricle enlargement 16 days after
injury. It has been shown that excitotoxicity-induced
inﬂammation through microglial release of cytokines
and free radicals played a central deleterious role47,48 and
that apoptotic pathways were implicated in similar
models of preterm brain injury49,50. However, autophagy-
mediated neuronal death has never been investigated in
this context.
Macroautophagy is an important physiological
mechanism of degradation present at a basal level com-
plementary to the proteasome system. A “controlled”
upregulation of autophagy has been considered for a long
time as a survival response, for instance, acting as an
alternative source of energy during starvation or as
a quality control step eliminating toxic metabolites,
defective organelles or intracellular pathogens23,51,52.
However, this dogma has been challenged about 30 years
ago by the description of dying cells without typical
morphological hallmarks of apoptosis or necrosis and
containing numerous autolysosomes27. This new mor-
phological type of cell death was coined “autophagic cell
death” and the missuse of the term led to a strong debate
on a possible pro-death role of autophagy in some stress
Fig. 7 Pharmacological inhibition of autophagy is protective against ibotenate-induced excitotoxicity in primary cortical neuronal
cultures. a Pretreatment with 3-methyadenine (3-MA) 1 h before ibotenate (Ibo) addition for 6 h prevents LC3-II increase (veh: 100 ± 5%; Ibo: 143.7 ±
7.8%; veh+ 3-MA: 64.6 ± 3.4%; Ibo+ 3-MA: 106.1 ± 6.7%) and SQSTM1 decrease (veh: 100 ± 1.4%; Ibo: 78.4 ± 3.4%; veh+ 3-MA: 131 ± 8.2%; Ibo+ 3-
MA: 104.3 ± 7.1%) induced by Ibo as shown by representative immunoblots and the corresponding quantiﬁcations. b 3-MA decreases neuronal death
as shown by reduced lactate deshydrogenase (LDH) release in the culture medium of cultured neurons (veh: 10 ± 1.7%; Ibo: 100 ± 4.3%; veh+ 3-MA:
8.6 ± 1.4%; Ibo+ 3-MA: 74.7 ± 7.5%). c E64/PepA pretreatment reduces neuronal death as indicated by a decrease in LDH release measured 6 h after
Ibo addition (veh DMSO: 16.8 ± 2.9; Ibo DMSO: 100 ± 5%; veh E64/PepA: 21.3 ± 5.8%; Ibo E64/PepA: 69.6 ± 9.7%). Values are mean ± SEM, *p < 0.05;
**p < 0.01; ***p < 0.001
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conditions10,34,35. In fact, “autophagic cell death” is a
distinct mechanism of cell death independent of apoptotic
and necrotic machinery that is observed in some speciﬁc
circumstances27,38,53. However, there is now evidences
and it is well accepted, that autophagy can be more fre-
quently involved in cell death as a trigger leading to
Fig. 8 Genetic inhibition of autophagy is protective against ibotenate-induced excitotoxicity in primary cortical neuronal cultures.
a Lentiviral transduction of shRNA directed against BECLIN1 (BECN1) (sc shRNA: 100 ± 1.9%; Becn1 shRNA: 43 ± 12.3%) and ATG7 (sc shRNA: 100 ±
7.4%; Atg7 shRNA: 63 ± 10.9%) proteins efﬁciently reduced the expression of both proteins. b, c Downregulation of both (b) BECN1 and (c) ATG7
prevents LC3-II increase ((b) veh sc shRNA: 100 ± 2.1%; Ibo sc shRNA: 135 ± 9.4%; veh Atg7 shRNA: 64.4 ± 9.1%; Ibo Atg7 shRNA: 60.8 ± 6.6%; (c) veh sc
shRNA: 100 ± 1.8%; Ibo sc shRNA: 125.6 ± 5.5%; veh Becn1 shRNA: 98.4 ± 4.6%; Ibo Becn1 shRNA: 100.6 ± 4.1%) and SQSTM1 decrease ((b) veh sc
shRNA: 100 ± 1.4 %; Ibo sc shRNA: 93 ± 3.4%; veh Atg7 shRNA: 109.5 ± 4%; Ibo Atg7 shRNA: 117.2 ± 3.6%; (c) veh sc shRNA: 100 ± 1.4%; Ibo sc shRNA:
91.3 ± 3.2%; veh Becn1 shRNA: 132.4 ± 19.3%; Ibo Becn1 shRNA: 119.4 ± 10.7%) induced by Ibo (6 h) as shown by representative immunoblots and
the corresponding quantiﬁcations. d Downregulation of both ATG7 and BECN1 has a neuroprotective effect as demonstrated by reduced
lactate deshydrogenase (LDH) release in the culture medium of cultured neurons (veh sc shRNA: 7.2 ± 1.4 %; veh Atg7 shRNA: 11.3 ± 1.9%; veh Becn1
shRNA: 15.9 ± 3%; Ibo sc shRNA: 100 ± 7%; Ibo Atg7 shRNA: 71.4 ± 6.3%; Ibo Becn1 shRNA: 68.8 ± 7%). Values are mean ± SEM, *p < 0.05; **p < 0.01;
***p < 0.001
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apoptotic or necrotic cell death (autophagy-mediated
cell death)20,21,29,34,38,54–57. Excitotoxicity and cerebral
HI are some of the conditions where autophagy is
enhanced58. Although some controversies exist32,33,59,
most of the studies using pharmacological inhibitors
such as 3-MA30,37 and especially those using speciﬁc and
genetic inhibition of atg20,29,31 revealed a deleterious
role of autophagy. They also supported the concept of a
strong interconnection between autophagic and apoptotic
mechanisms in perinatal cerebral HI19,20,32,60. The present
study is the ﬁrst to demonstrate a death-promoting role of
autophagy in a preterm model of excitotoxic brain lesion.
Our results strongly suggest that autophagy is enhanced
in neurons after ibotenate injection in the brain of rat
pups, as also demonstrated in primary cortical neurons
cultures. Autophagosome formation is increased from 6 h
as shown by a higher level of LC3-II and more LC3-
positive dots. This increase was not due to impaired
autophagosome degradation that would have occurred if
lysosomal function was defective. In fact, p62/SQSTM1
is also degraded and autolysosomes are increased in
neurons as indicated by larger and more numerous
LAMP1- and CTSB-positive dots. This result is consistent
with EM observations showing the presence of both
autophagosome-like multimembrane vesicles and
autolysosome-like dense structures in dying neurons of
ibotenate-injected rat pups. We provide here, especially in
primary neuronal cultures, compiling evidences demon-
strating that the autophagy ﬂux is increased by ibotenate
treatment. Both Western blots against LC3 and p62/
SQSTM1 with or without E64/pepstatinA co-treatments
and the use of the GFP-RFP-LC3 construct lead to the
same conclusion, ibotenate treatment is increasing
autophagosome formation and degradation. Moreover,
the GFP-RFP-LC3 construct we used is less sensitive to
acidiﬁcation comparing to other constructs, such as
the mKate2-pHluorin-hLC361, suggesting that the num-
ber of autolysosomes could be theoretically under-
estimated. Our in vitro data on primary cortical neuronal
cultures also strongly argued for the induction of an
autophagy-mediated neuronal death by ibotenate. Inhi-
bition of autophagy, not only pharmacologically with
3-MA or E64/PepA, but also genetically by down-
regulating two important ATG proteins, ATG7 or
BECN1, was neuroprotective as previously shown when
excitotoxicity was induced in hypoxic conditions29.
Even if caution is necessary concerning the limited
speciﬁcity of 3-MA as an autophagy inhibitor22, we here
clearly showed that the dose used in vivo efﬁciently
prevented autophagy (decrease in LC3-II level and
SQSTM1/p62 degradation). Furthermore, since it is
known that permanent impaired autophagy leads to
neurodegeneration (as it would be the case with long term
genetic inhibition of autophagy)43, the use of 3-MA was
appropriate to study long term effect on brain lesion
in vivo (16 days after the insult). When ibotenate-
enhanced autophagy was prevented by 3-MA treatment,
both CASP3 activation and calpain-dependent cleavage of
SPTAN (used as an indicator of necrotic cell death
characterized by a calcium increase) were signiﬁcantly
decreased. Moreover, ultrastructural observations showed
condensed chromatin in nuclei of dying and highly
autophagic neurons. Mixed features of apoptosis and
autophagy were also observed in rodent models of peri-
natal cerebral HI19,20,30,31,60 and we previously demon-
strated that autophagy could contribute to apoptosis
using widely recognized apoptotic stimuli in primary
cortical neuron cultures62. The beneﬁcial effect of 3-MA
on neuronal cell death, including apoptosis, resulted here
in a strong signiﬁcant neuroprotective effect at long term
on both GM and WM, suggesting a crucial role of
autophagy in mediating (apoptotic and necrotic) cell
death. Studies on perinatal cerebral HI models have also
shown that autophagy inhibition could be neuroprotective
and reduce apoptosis20,30,31 suggesting that the transient
inhibition of autophagy could be a promising strategy to
protect the immature brain against excitotoxic insults.
It has been shown that females are more resistant to
perinatal cerebral injury than males, especially in the
context of cerebral HI and after moderate lesions, in
rodents as well as in humans63–66. The reason of this
gender difference is still unclear, but sex-dependent cell
death pathways have been recognized after perinatal
cerebral HI, especially more active caspase-dependent
pathways in females66–68. In the present study, we also
found a stronger CASP3 activation and a more important
variability in females in almost all the different parameters
investigated. However, mean ibotenate-induced brain
lesion volume was similar in both genders. Moreover, the
protective effect of 3-MA against both ibotenate-induced
autophagy and cerebral lesions was as efﬁcient in males as
in females.
In conclusion, we showed for the ﬁrst time that
enhanced autophagy could mediate cell death in a pre-
mature model of excitotoxic brain damage. Autophagy
inhibition in this severe model is very promising since the
protective effect obtained is similar or even better to other
previously described neuroprotectants such as caspases
inhibitors69, erythropoietin70,71, BDNF72,73, melatonin74
or magnesium sulfate75,76. Interestingly, we recently
demonstrated that autophagy is enhanced in dying neu-
rons in the ventrolateral nucleus of the thalamus and the
lentiform nucleus of term newborns with severe HIE31,60.
Apoptotic markers were also expressed in dying highly
autophagic neurons, arguing for a possible association
between autophagy and apoptosis also in humans.
Moreover an increased presence of autophagosomes
(LC3-positive dots) was recently demonstrated in WM
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injury of extremely preterm infants77. These 3 different
studies using human newborn brain sections31,60,77 and
the important neuroprotection obtained with 3-MA in
the present study in a severe model of cPVL suggest
that enhanced neuronal autophagy could be a promising
target. The development of strategies transiently inhibit-
ing autophagy could pave the way for new therapies
against neonatal severe excitotoxic injuries such as HIE
and cPVL.
Material and methods
Primary cortical neuronal cultures
Primary neuronal cultures were prepared according
to the Swiss laws for the protection of animals from
pieces of cortices of 2-day-old Sprague-Dawley rat pups
(Janvier Labs, Mayenne, France). The procedures were
approved by the Vaud Cantonal Veterinary Ofﬁce.
After dissection, dissociation and trituration, neurons
were plated in neurobasal medium (Gibco, NY, USA;
21103–049) supplemented with 2% B27 (Gibco;
17504044), 0.5 mM L-glutamine (Sigma, MO, USA;
49419) and 100 μg/ml penicillin-streptomycin (Gibco;
15140122) and maintained at 37 °C with a 5% CO2-con-
taining atmosphere as described previously78. Western
blot analyses were done on neurons plated at a density
of ~7 × 105 cells/dish (35-mm poly-D-lysine pre-coated
dishes (BD Biosciences, NJ, USA; 356467) and at a
density of ~3 × 105 cells on 12-mm glass coverslips coated
with 0.01% poly-L-lysine (Sigma; P4832) for immunocy-
tochemistry and imaging. For all the Western blots or
imaging results, at least three independent experiments,
each involving two or three culture dishes or coverslips,
were performed.
Pharmacological treatments
Primary cortical neuronal cultures were pre-treated for
1 h with 10mM 3-methyladenine (3-MA) (Sigma;
M9281), 5 mM EGTA (Sigma; E0396) or 40 μM MK801
(Sigma; M107). For inhibition of lysosomal degradation, a
cocktail of 10 μg/ml pepstatin A1 (PepA) (Sigma; P5318)
and 10 μg/ml E64 (Sigma; E3132) was applied for 4 h prior
to 50 μM ibotenic acid (Enzo Life Sciences, NY, USA;
BML-EA120–0001) addition.
Quantiﬁcation of cell death with lactate dehydrogenase
release
Cell death was assayed by measurement of LDH
released in the medium using the Cytotox 96 non-
radioactive cytotoxicity assay kit (Promega, WI, USA;
G1780) as previously described78. LDH measurements
were normalized with respect to the values of ibotenate-
treated neurons 6 h after the ibotenate addition.
Knockdown of ATG using lentiviral vectors
Downregulation of Atg genes were performed with
pLKO lentiviral vectors (Open Biosystems/Dharmacon,
CO, USA) expressing rat-speciﬁc shRNA sequences
from TRC (the RNAi consortium) library as described
previously62. A combination of TRCN0000092163
and TRCN0000092166 for Atg7 (GenBankTM
NM_001012097), TRCN0000033552 for Becn1 (Gen-
BankTM NM_053739.2) and a pLKO vector containing
scrambled shRNA (Open Biosystems/Dharmacon) as
control vector were used. Primary cortical neuron cul-
tures were infected at DIV7 with 50 ng of the viral capsid
protein p24/ml culture medium for each vector.
mRFP-GFP-LC3 plasmid transfection and quantiﬁcation
Neurons on coverslips were transfected with the tan-
dem mRFP-GFP-LC3–expressing plasmid ptfLC3
(Addgene, MA, USA; 21074)79 using Lipofectamine 2000
(Invitrogen, CA, USA; 11668-019) as described pre-
viously29. Coverslips were ﬁxed with 4% paraformalde-
hyde for 15 min. Confocal images were acquired using a
Zeiss LSM 710 Meta confocal laser scanning microscope.
Total LC3-positive dots (GFP+ RFP+ and GFP− RFP+
dots), early autophagosomes (GFP+ RFP+ dots) and
mature or late autophagosomes (GFP− RFP+ dots) were
analyzed using ImageJ software and expressed as a num-
ber of positive dots per neuron per µm2.
Rat model of preterm excitotoxic brain injury
All experiments were performed in accordance with the
Swiss laws for the protection of animals and were
approved by the Vaud Cantonal Veterinary Ofﬁce. Ten µg
of ibotenate (diluted 5 µg/µl in acetic acid 0.02%) were
stereotaxically injected under isoﬂurane anesthesia (2.5%)
in the subcortical WM at the level of the right cingulum
(1 mm posterior and 1mm right from Bregma and
1.5 mm depth from the skull surface) of 5-day-old male
and female Sprague Dawley rats (Janvier Labs) (model
adapted from Marret and colleagues (1995)42). The con-
trol animals received an injection of the same volume of
vehicle (acetic acid 0.02%). The pharmacological autop-
hagy inhibitor 3-MA (2 µl of 30 mg/ml in saline) was
stereotaxically injected in the right lateral ventricle
(0.5 mm posterior and 1mm right from Bregma and
2.5 mm depth from the skull surface) just before ibotenate
injection. Control animals received an injection of the
same volume of saline as vehicle. After recovering from
anesthesia, rat pups returned to the dam until sacriﬁce.
Electron microscopy
Electron microscopy (EM) was done on rat brains ﬁxed
following intracardiac perfusion with 2.5% glutaraldehyde
and 2% paraformaldehyde in cacodylate buffer (0.1 M,
pH7.4) as previously described80.
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Immunoblotting
Immunoblots were performed on extracts from primary
neuronal cultures or from cortex collected in lysis buffer
(20mM HEPES, pH 7.4, 10mM NaCl, 3 mM MgCl2,
2.5mM EGTA, 0.1mM dithiothreitol, 50mM NaF, 1mM
Na3VO4, 1% Triton X-100 and a protease inhibitor cock-
tail (Sigma;11873580001)29. Protein concentration was
determined using a Bradford assay. Proteins (20–40 µg)
were separated on 10, 12 or 15% polyacrylamide gels and
analyzed by immunoblotting. Antibodies were diluted in
the blocking solution containing 0.1% casein (Sigma;
C8654). Primary antibodies used were: anti-ATG7
(sc-33211) rabbit polyclonal and anti-BECN1 (sc-11427)
rabbit polyclonal from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); anti-LC3 (ab48394) rabbit polyclonal
from Abcam (MA, USA); anti-cleaved CASP3/caspase-3
(9661) rabbit polyclonal from Cell Signalling Technology
(MA; USA); anti-SQSTM1 (P0067) rabbit polyclonal
from Sigma; anti-FODRIN/SPECTRIN (FG6090) mouse
monoclonal from Enzo Life Sciences and anti-ACTA/α-
ACTIN (MAB1501) mouse monoclonal from Millipore/
Merck (MA, USA). Secondary antibodies were polyclonal
goat anti-mouse or anti-rabbit IgG from LiCOR (IRDye
680 or IRDye 800). Protein bands were visualized with
the Odyssey Infrared Imaging System (LICOR, NE, USA).
Odyssey v1.2 software (LICOR) was used for analysis.
Values were normalized with respect to ACTIN.
Immunohistochemistry
Immunostainings were performed on 20μm cryostat
brain sections from rat pups perfused transcardially with
4% paraformaldehyde in 0.1 mol/L PBS (pH 7.4)29. PBS
with 15% donkey serum and 0.3% Triton X-100 were used
for blocking and permeabilization for 30–45min. Primary
antibodies diluted in PBS with 1.5% donkey serum and
0.1% Triton X-100 overnight at 4 °C were: anti-cleaved
CASP3/caspase-3 (9661) rabbit polyclonal from Cell
Signalling Technology; anti-LC3 (ab48394) rabbit poly-
clonal from Abcam; anti-CTSB/cathepsin B (06–480),
anti-MAP2 (AB5622) rabbit polyclonal antibodies, anti-
RBFOX3/NeuN (MAB377) and anti-LAMP1 (428017)
mouse monoclonal antibodies from Merk/Millipore.
Secondary antibodies were diluted in PBS for 2 h at room
temperature.
For immunoﬂuorescence labeling, Alexa Fluor donkey-
anti-rabbit or mouse secondary antibodies (Invitrogen;
A21202, A21203, A21206, A21207) were used. A LSM
710 Meta confocal microscope (Carl Zeiss) were used for
confocal laser microscopy. Images were processed with
LSM 510 software and mounted using Adobe Photoshop.
Quantiﬁcation of autophagic and lysosomal labeling
Confocal images of ﬂuorescent immunostaining against
LC3, CTSB and LAMP1 were acquired using the LSM 710
Meta confocal laser scanning microscope (Carl Zeiss) and
images were then processed with Adobe Photoshop CC
2015. Positive dots were quantiﬁed using ImageJ software
and expressed as a number of positive dots per neuron
per μm2 and, for the lysosomal markers CTSB and
LAMP1, as a mean dot area per neuron per μm2.
Cerebral regions volume and WM thickness measurements
Sixteen days after the injury (at P21) brains were per-
fused, frozen and entirely cut into series of 20 μm coronal
sections spaced at 500μm disposed in series. On a cresyl
violet-stained series, the ipsilateral volume of the total
surviving tissue, the cortex and the lateral ventricle were
measured using the Zen Blue software (Zeiss). The
volumes were then expressed as a percentage of the total
brain volume.
WM thickness were measured on 3 consecutive cresyl
violet-stained sections starting from the ﬁrst on which
the genu of the corpus callosum appeared (approx.
0.6–0.8mm anterior to the Bregma according to the
“atlas of the rat brain in stereotaxic coordinates at P21” of
Khazipov et al., http://www.ialdevelopmentalneurobiology.
com/images/atlases/Atlas-p21.pdf81). The thickness of the
ipsilateral corpus callosum (on the midline) and the sub-
cortical WM at the level of the cingulum (1.4 mm apart
from the midline) and at the beginning of the external
capsule (2mm apart from the midline) were measured
parallel to the midline with the Zen Blue software (Zeiss).
Values are expressed as a mean of the three measures.
Statistics
Values were expressed as mean values ± standard error
of the mean (SEM). Data were analyzed statistically using
GraphPad PRISM (version 7.03) software. The normality
of the distribution was ﬁrst tested using Shapiro–Wilk
tests. Parametric data were analyzed using a Welch’s
ANOVA test (one-way ANOVA with unequal variances)
followed by a post-hoc Tukey-Kramer test. Non-
parametric data were analyzed using a Kruskal–Wallis
test (non-parametric analog of the one-way ANOVA)
followed by a post-hoc Steel-Dwass. P < 0.05 was chosen
as threshold for statistical signiﬁcance.
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